Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence
Nelson B. Rodrigues, Roger S. McIntyre, Orly Lipsitz, et al.
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 8, pp. 1031-1040
Closed Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation
Roger S. McIntyre, Joshua D. Rosenblat, Charles B. Nemeroff, et al.
American Journal of Psychiatry (2021) Vol. 178, Iss. 5, pp. 383-399
Open Access | Times Cited: 476
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders
Felicia Ceban, Joshua D. Rosenblat, Kevin Kratiuk, et al.
CNS Drugs (2021) Vol. 35, Iss. 9, pp. 925-934
Closed Access | Times Cited: 61
Oral ketamine for depression: An updated systematic review
Shakila Meshkat, Sipan Haikazian, Joshua D. Di Vincenzo, et al.
The World Journal of Biological Psychiatry (2023) Vol. 24, Iss. 7, pp. 545-557
Closed Access | Times Cited: 34
The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: A systematic review
Joshua D. Di Vincenzo, Ashley Siegel, Orly Lipsitz, et al.
Journal of Psychiatric Research (2021) Vol. 137, pp. 232-241
Closed Access | Times Cited: 42
Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada
Carson Chrenek, Bryan Duong, Atul Khullar, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 7
Real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression
Farhan Fancy, Nelson B. Rodrigues, Joshua D. Di Vincenzo, et al.
Bipolar Disorders (2022) Vol. 25, Iss. 2, pp. 99-109
Closed Access | Times Cited: 27
The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis
Tuuli M. Hietamies, L. Alison McInnes, Andrew Klise, et al.
Journal of Affective Disorders (2023) Vol. 335, pp. 484-492
Open Access | Times Cited: 13
A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions
Nelson B. Rodrigues, Roger S. McIntyre, Orly Lipsitz, et al.
Journal of Affective Disorders (2020) Vol. 282, pp. 160-164
Closed Access | Times Cited: 33
Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant Depression
Eric McMullen, Yena Lee, Orly Lipsitz, et al.
Advances in Therapy (2021) Vol. 38, Iss. 6, pp. 2795-2820
Open Access | Times Cited: 32
Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series
Orly Lipsitz, Joshua D. Di Vincenzo, Nelson B. Rodrigues, et al.
American Journal of Geriatric Psychiatry (2021) Vol. 29, Iss. 9, pp. 899-913
Closed Access | Times Cited: 31
Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study
Alina Wilkowska, Adam Włodarczyk, Maria Gałuszko‐Węgielnik, et al.
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 2637-2646
Open Access | Times Cited: 27
Blood pressure changes during ketamine infusion for the treatment of depression
Mina Ansari, Brian Pittman, Daniel S. Tylee, et al.
General Hospital Psychiatry (2024) Vol. 90, pp. 62-67
Closed Access | Times Cited: 4
Letter to the editor in response to: Blood pressure changes during ketamine infusion for the treatment of depression
Kevin Skoblenick, Ryan Yip, Atul Khullar, et al.
General Hospital Psychiatry (2025) Vol. 94, pp. 110-111
Closed Access
Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress
Michael D. Kritzer, Nicholas Mischel, Jonathan R. Young, et al.
Annals of Clinical Psychiatry (2021), Iss. Volume 33, No. 4
Open Access | Times Cited: 26
Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review
Vivian W. L. Tsang, Brendan Tao, Shannon Dames, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 9
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen Wen, Wenjing Zhao, Xing Xia, et al.
Pharmacology Biochemistry and Behavior (2024) Vol. 242, pp. 173773-173773
Closed Access | Times Cited: 3
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment
Jason Ng, Leanna M.W. Lui, Joshua D. Rosenblat, et al.
Psychopharmacology (2021) Vol. 238, Iss. 4, pp. 917-926
Closed Access | Times Cited: 23
Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence
Orly Lipsitz, Roger S. McIntyre, Nelson B. Rodrigues, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 105, pp. 110126-110126
Closed Access | Times Cited: 19
Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence
Orly Lipsitz, Roger S. McIntyre, Nelson B. Rodrigues, et al.
CNS Spectrums (2020) Vol. 27, Iss. 3, pp. 322-330
Closed Access | Times Cited: 19
Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition
Hanadi Ajam Oughli, Marie Anne Gebara, Adam Ciarleglio, et al.
American Journal of Geriatric Psychiatry (2022) Vol. 31, Iss. 3, pp. 210-221
Closed Access | Times Cited: 11
Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression
Nelson B. Rodrigues, David Chen‐Li, Joshua D. Di Vincenzo, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 4, pp. 375-381
Open Access | Times Cited: 2
Targeting inflammasome complexes as a novel therapeutic strategy for mood disorders
Aline Silva de Miranda, Eliana Cristina de Brito Toscano, Jason C. O’Connor, et al.
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 5, pp. 401-418
Closed Access | Times Cited: 2
Polish standard of treatment with racemic ketamine for patients with depressive disorders developed by a Working Group appointed by the National Consultant in the field of psychiatry
Piotr Gałecki, Katarzyna Bliźniewska-Kowalska, Wiesław Jerzy Cubała, et al.
Psychiatria Polska (2024) Vol. 58, Iss. 3, pp. 377-401
Open Access | Times Cited: 2
Ketamine use in pediatric depression: A systematic review
Shakila Meshkat, Joshua D. Rosenblat, Roger Ho, et al.
Psychiatry Research (2022) Vol. 317, pp. 114911-114911
Closed Access | Times Cited: 10
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth
Noah Chisamore, Kevork Danayan, Nelson B. Rodrigues, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 8, pp. 775-783
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top